Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy.

Trial Profile

Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Catumaxomab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer; Peritoneal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CatuNeo
  • Most Recent Events

    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
    • 13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 13 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top